sofosbuvir/velpatasvir/voxilprevir (Vosevi)

following a full submission:

sofosbuvir-velpatasvir-voxilaprevir (Vosevi®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.

SMC restriction: for patients who:
(1) Have failed to achieve a sustained virologic response (SVR) with a direct-acting anti-viral (DAA)
or
(2) are DAA-naïve, have genotype 3 (GT3) HCV infection, with or without cirrhosis,
and are suitable for treatment with an eight-week course.

Sofosbuvir-velpatasvir-voxilaprevir was associated with high rates of SVR in adults with chronic HCV who had failed to achieve a response with DAA medicines and in those who were naïve to these medicines.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sofosbuvir-velpatasvir-voxilaprevir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.